Utz I - Search Results

1

Novel RHD alleles with weak hemagglutination and genetic Exon 9 diversity: weak D Types 45.1, 75, and 76.

Gassner C, Utz I, Schennach H, Ramoni A, Steiner H, Scholz S, Kreklau U, Körmöczi GF. Gassner C, et al. Among authors: utz i. Transfusion. 2013 Nov;53(11 Suppl 2):2954-9. doi: 10.1111/trf.12180. Epub 2013 Apr 3. Transfusion. 2013. PMID: 23550956

2

Fyx is associated with two missense point mutations in its gene and can be detected by PCR-SSP.

Gassner C, Kraus RL, Dovc T, Kilga-Nogler S, Utz I, Mueller TH, Schunter F, Schoenitzer D. Gassner C, et al. Among authors: utz i. Immunohematology. 2000;16(2):61-7. Immunohematology. 2000. PMID: 15373620

3

Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700.

Utz I, Spitaler M, Rybczynska M, Ludescher C, Hilbe W, Regenass U, Grunicke H, Hofmann J. Utz I, et al. Int J Cancer. 1998 Jul 3;77(1):64-9. doi: 10.1002/(sici)1097-0215(19980703)77:1<64::aid-ijc11>3.0.co;2-9. Int J Cancer. 1998. PMID: 9639395

4

Protein kinase C isoenzymes, p53, accumulation of rhodamine 123, glutathione-S-transferase, topoisomerase II and MRP in multidrug resistant cell lines.

Utz I, Gekeler V, Ise W, Beck J, Spitaler M, Grunicke H, Hofmann J. Utz I, et al. Anticancer Res. 1996 Jan-Feb;16(1):289-96. Anticancer Res. 1996. PMID: 8615623

5

Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance.

Hofmann J, Gekeler V, Ise W, Noller A, Mitterdorfer J, Hofer S, Utz I, Gotwald M, Boer R, Glossmann H, et al. Hofmann J, et al. Among authors: utz i. Biochem Pharmacol. 1995 Mar 1;49(5):603-9. doi: 10.1016/0006-2952(94)00479-6. Biochem Pharmacol. 1995. PMID: 7887974

6

The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance.

Utz I, Hofer S, Regenass U, Hilbe W, Thaler J, Grunicke H, Hofmann J. Utz I, et al. Int J Cancer. 1994 Apr 1;57(1):104-10. doi: 10.1002/ijc.2910570119. Int J Cancer. 1994. PMID: 7908658

7

Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).

Hofmann J, Utz I, Spitaler M, Hofer S, Rybczynska M, Beck WT, Herrmann DB, Grunicke H. Hofmann J, et al. Among authors: utz i. Br J Cancer. 1997;76(7):862-9. doi: 10.1038/bjc.1997.476. Br J Cancer. 1997. PMID: 9328144 Free PMC article.

8

PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1.

Spitaler M, Utz I, Hilbe W, Hofmann J, Grunicke HH. Spitaler M, et al. Among authors: utz i. Biochem Pharmacol. 1998 Oct 1;56(7):861-9. doi: 10.1016/s0006-2952(98)00107-5. Biochem Pharmacol. 1998. PMID: 9774148

9

Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.

Gekeler V, Boer R, Uberall F, Ise W, Schubert C, Utz I, Hofmann J, Sanders KH, Schächtele C, Klemm K, Grunicke H. Gekeler V, et al. Among authors: utz i. Br J Cancer. 1996 Sep;74(6):897-905. doi: 10.1038/bjc.1996.454. Br J Cancer. 1996. PMID: 8826855 Free PMC article.

10

Role of protein kinases in antitumor drug resistance.

Grunicke H, Hofmann J, Utz I, Uberall F. Grunicke H, et al. Among authors: utz i. Ann Hematol. 1994;69 Suppl 1:S1-6. doi: 10.1007/BF01757347. Ann Hematol. 1994. PMID: 8061107 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters